Evidence map›Paper›PMID 37299611›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Tantalum Nitride-Based Theranostic Agent for Photoacoustic Imaging-Guided Photothermal Therapy in the Second NIR Window.

Huixi Yi, Gaoyang Yan, Jinzhen He, Jiani Zhuang, Chengzhi Jin, Dong-Yang Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Tantalum-Based Nanomaterials: From Properties to Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Huixi YiGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, National Medical Products Administration, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Gaoyang YanGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, National Medical Products Administration, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Jinzhen HeGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, National Medical Products Administration, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Jiani ZhuangGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, National Medical Products Administration, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Chengzhi JinGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, National Medical Products Administration, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Dong-Yang ZhangGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, National Medical Products Administration, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Guangzhou Medical University · CNState Key Laboratory of Respiratory Disease · CNNational Medical Products Administration · CN

Funding

National Natural Science Foundation of China 22207019the National Key Research and Development Program 2022YFC2603900The Natural Science Foundation of Guangdong Province 2022A1515011796
6 · The paper itself

Abstract

Metal nitrides show excellent photothermal stability and conversion properties, which have the potential for photothermal therapy (PTT) for cancer. Photoacoustic imaging (PAI) is a new non-invasive and non-ionizing biomedical imaging method that can provide real-time guidance for precise cancer treatment. In this work, we develop polyvinylpyrrolidone-functionalized tantalum nitride nanoparticles (defined as TaN-PVP NPs) for PAI-guided PTT of cancer in the second near-infrared (NIR-II) window. The TaN-PVP NPs are obtained by ultrasonic crushing of massive tantalum nitride and further modification by PVP to obtain good dispersion in water. Due to their good absorbance in the NIR-II window, TaN-PVP NPs with good biocompatibility have obvious photothermal conversion performance, realizing efficient tumor elimination by PTT in the NIR-II window. Meanwhile, the excellent PAI and photothermal imaging (PTI) capabilities of TaN-PVP NPs are able to provide monitoring and guidance for the treatment process. These results indicate that TaN-PVP NPs are qualified for cancer photothermal theranostics.

Indexed as

photoacoustic imagingphotothermal therapysecond near-infrared windowtantalum nitride nanoparticlestheranostics

Identifiers

PMID37299611
PMCPMC10254667
OpenAlexW4378086834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.